-
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
21 Jan 2025 14:12 GMT
… -2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold … biomarkers of ALS.
About ALS
Amyotrophic lateral sclerosis (ALS, also known as motor …
-
Zydus Lifesciences gets USFDA nod to conduct Phase II(b) clinical trial for Usnoflast for Amyotrophic Lateral Sclerosis
19 Jan 2025 13:00 GMT
… inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS).
Under the leadership of … Bowel Disease (IBD) and Multiple Sclerosis (MS). The USFDA has granted …
-
At Light of Day, Boss calls report he's a billionaire 'fake news'
22 Jan 2025 00:14 GMT
… along that line Parkinsons, (and amyotrophic lateral sclerosis and progressive supranuclear palsy) would …
-
Real-World Study Highlights Positive Treatment Benefits of Tofersen on ALS Disease Progression, Function
21 Jan 2025 23:16 GMT
… -approved medication for patients with amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase …
-
TREM2 agonists disclosed in Roche patent
21 Jan 2025 22:48 GMT
… useful for the treatment of amyotrophic lateral sclerosis, Alzheimer’s disease, frontotemporal dementia … , multiple sclerosis, Nasu-Hakola disease, Parkinson’s …
-
Tofersen improves functional independence in SOD-1 ALS
21 Jan 2025 20:16 GMT
… 1% to 2% of all amyotrophic lateral sclerosis patients,” Sean E. Smith, MD …
-
New Bedford man sentenced for stealing veterans benefits
21 Jan 2025 18:51 GMT
… Corps who was suffering from amyotrophic lateral sclerosis (ALS), noted the release. After …
-
New Orleans Saints legend Steve Gleason enjoys snow with his family
21 Jan 2025 18:12 GMT
… ;s disease, also known as amyotrophic lateral sclerosis.Gleason has dedicated his life … ;s disease, also known as amyotrophic lateral sclerosis.
Gleason has dedicated his life …
-
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
21 Jan 2025 17:07 GMT
… 1 trial in patients with Amyotrophic Lateral Sclerosis (ALS) (reported in February 2024 …
-
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
21 Jan 2025 13:31 GMT
… developed for the treatment of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson’s Disease …